Literature DB >> 17013580

[Lipometabolic disorder--cholesterol and triglycerides].

C Luley1.   

Abstract

Resorption inhibitors for cholesterol are commonly applied today in case of hypercholesterolemia in addition to statins. This combination therapy reduces the value of the LDL concentration by 50-60%. A target value of 100 mg/dl should be adjusted in case of high-risk patients in order to also decrease coronary risk. The significance of the triglycerides level is also becoming increasingly important, for it describes a high cardiovascular risk due to an increase of adiposity and diabetes. Such a dysfunction in storage and release of fatty lipids from triglycerides is treated dependent on severity: Patients with slightly elevated values (> 200 mg/dl) should change their habits (e.g. balanced diet, abstinance of alcohol, exercise) if necessary followed by application of fibrates, omega-3 fatty acids or nicotinic acid. These medicamentous measures are inevitable and must be applied immediately in case patients having values >1000 mg/dl.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17013580     DOI: 10.1007/s00392-006-1804-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  5 in total

Review 1.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors:  James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

2.  Addition of glucose to a fatty meal delays chylomicrons and suppresses VLDL in healthy subjects.

Authors:  S Westphal; A Leodolter; S Kahl; J Dierkes; P Malfertheiner; C Luley
Journal:  Eur J Clin Invest       Date:  2002-05       Impact factor: 4.686

3.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

4.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

5.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  5 in total
  3 in total

1.  Hormonal status modulates circulating endothelial progenitor cells.

Authors:  Daniel Bulut; Nadine Albrecht; Matthias Imöhl; Bülent Günesdogan; Nadine Bulut-Streich; Jan Börgel; Christoph Hanefeld; Michael Krieg; Andreas Mügge
Journal:  Clin Res Cardiol       Date:  2007-02-26       Impact factor: 5.460

2.  Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association.

Authors:  U Laufs; H Nef; H Möllmann; F Custodis; M Böhm
Journal:  Clin Res Cardiol       Date:  2007-12-18       Impact factor: 5.460

3.  Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany.

Authors:  Jacqueline Müller-Nordhorn; Heike Englert; Karl Wegscheider; Hendrike Berger; Frank Sonntag; Heinz Völler; Wolfgang Meyer-Sabellek; Thomas Reinhold; Eberhard Windler; Hugo A Katus; Stefan N Willich
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.